BridgeMD
New treatment option for Age-Related Macular Degeneration (AMD)
Official title Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment
ClinicalTrials.gov ID: NCT07500324
What this study is testing
- What it's testing
- This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration, diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Ability to understand the study procedures and provide written informed consent
- Willingness and ability to comply with study procedures and visits For case people:
- Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)
- Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)
You likely can't join if
- Age \< 18 years
- Presence of infectious ocular diseases
- Alterations in the electrophoretic profile of gamma globulins
See the full eligibility criteria
- Age ≥ 18 years
- Ability to understand the study procedures and provide written informed consent
- Willingness and ability to comply with study procedures and visits For case people:
- Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)
- Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)
- Patients undergoing surgery for primary or recurrent retinal detachment For control people:
- Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders)
- Outpatients with no documented retinal diseases
- For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina
- Age \< 18 years
- Presence of infectious ocular diseases
- Alterations in the electrophoretic profile of gamma globulins
The study team makes the final eligibility decision.
Where it's taking place
- Roma, Italy, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Roma, Italy, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.